Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Baseline Comparator Device Clear all

Conditions: Prediabetes, Diabetes, High Cholesterol/Hyperlipidemia, Obesity & Overweight, Triglycerides, HDL Cholesterol
Interventions: Bottarga, Comparator; Other
Lead sponsor: Cambridge Health Alliance; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Sommerville, Massachusetts

Conditions: Rheumatoid Arthritis (RA
Interventions: Peer Coach, Healthy Horizons; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Autism Spectrum Disorder
Interventions: CICADAS only, PEERS + CICADAS and then no-contact, PEERS + Active Comparator and then no-contact; Other
Lead sponsor: Posit Science Corporation; Industry
Eligibility: 11 Years to 18 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Oral Health
Interventions: Prototype 1, Prototype 2, Marketed Comparator; Other
Lead sponsor: Kenvue Brands LLC; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Iron Deficiency Anaemia, Iron Deficiency Anemia
Interventions: Iron isomaltoside/ferric derisomaltose, Iron sucrose; Drug
Lead sponsor: Pharmacosmos A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 114
States / cities: Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 83 more

Conditions: Microbiome, Cytokines, Plaque, Gingivitis, Gingival Bleeding
Interventions: Distilled Water, Marketed Comparator 1, Marketed Comparator 2, Prototype Rinse 1, Prototype Rinse 2; Other
Lead sponsor: Kenvue Brands LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Somerville, Massachusetts

Conditions: Chronic Pain
Interventions: CORPs Intervention, Minimally Enhanced Usual Care (MEUC); Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: Minneapolis, Minnesota • Portland, Oregon • Nashville, Tennessee + 1 more

Conditions: Chronic Pain
Interventions: Whole Health Team (WHT) Intervention Arm, Primary Care Group Education (PC-GE) Intervention Arm, Usual Primary Care (UPC) Arm; Behavioral
Lead sponsor: San Francisco Veterans Affairs Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 793 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 6
States / cities: San Francisco, California • West Haven, Connecticut • Tampa, Florida + 3 more

Conditions: Invasive Mould Infection
Interventions: EL219, Active Comparator- IV Antifungal (LAmB or voriconazole); Drug
Lead sponsor: Elion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 11
States / cities: Birmingham, Alabama • Sacramento, California • Augusta, Georgia + 7 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: WearME-Pro Patch System, FDA-cleared handheld spirometer (reference comparator), Cardea SOLO ECG patch (optional subset; exploratory HR reference); Device
Lead sponsor: LASARRUS Clinic and Research Center; Industry
Eligibility: 21 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Baltimore, Maryland • Salisbury, Maryland

Conditions: Critical Illness, Delirium, Cognitive Impairment, Cognitive Decline, Alzheimer's Disease, Dementia, Circadian Dysrhythmia, Sleep Disturbance
Interventions: SLEEP + COG, COG, SLEEP, AC; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 60 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Parkinson's Disease Psychosis
Interventions: Pimavanserin, Quetiapine; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years and older
Enrollment: 358 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 24
States / cities: Tucson, Arizona • Loma Linda, California • Palo Alto, California + 20 more

Conditions: Diabetes Mellitus, Diabetic Retinopathy
Interventions: EyePromise DVS, EyePromise DVS plus EyePromise EZTears; Dietary Supplement
Lead sponsor: ZeaVision, LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: HIV/AIDS
Interventions: PrEP@Home System, Standard of Care; Behavioral · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 318 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 5
States / cities: Atlanta, Georgia • Boston, Massachusetts • Jackson, Mississippi + 2 more

Conditions: Iron Deficiency Anaemia, Iron Deficiency Anemia, Chronic Kidney Disease
Interventions: Iron isomaltoside/ferric derisomaltose, Iron sucrose; Drug
Lead sponsor: Pharmacosmos A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,538 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 141
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Chula Vista, California + 96 more

Conditions: Arthritis Multiple Joint
Interventions: Botulinum Toxin Type A, Steroid - Triamcinolone Acetonide, Lidocaine; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Lower Back Pain
Interventions: Pregnenolone, Placebo; Drug
Lead sponsor: Durham VA Medical Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Human Papillomavirus Infection
Interventions: APTIMA HPV Assay, FDA-Approved HPV DNA Test; Device
Lead sponsor: Gen-Probe, Incorporated; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 12,896 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 17
States / cities: Jonesboro, Arkansas • Canoga Park, California • Los Angeles, California + 13 more

Conditions: Migraine
Interventions: Active Comparator, Sham Comparator; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Baseline Epidemiologic Assessment
Interventions: MorphaBond ER, Comparator Drug; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: Not listed
Enrollment: 17,566 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Basking Ridge, New Jersey

Conditions: Hypertension
Interventions: Heart Health and Nutrition for Life (HHNL), Self-Measured Blood Pressure; Behavioral
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 84 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Primary Myelofibrosis, MPN-associated Myelofibrosis
Interventions: Pomalidomide 0.5 mg, Placebo, Pomalidomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 17
States / cities: Scottsdale, Arizona • Los Angeles, California • Gainesville, Florida + 12 more

Conditions: Social Determinants of Health (SDOH), Hypertension, Diabetes Mellitus, Hypercholesterolaemia
Interventions: Community Health Worker intervention, Usual Care; Other
Lead sponsor: Sairam Parthasarathy; Other
Eligibility: 18 Years and older
Enrollment: 740 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Tucson, Arizona

Conditions: Rett Syndrome
Interventions: Drug: Bionetide, Placebo; Drug
Lead sponsor: Biomed Industries, Inc.; Industry
Eligibility: 5 Years to 20 Years · Female only
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 12
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 9 more

Search by objective public record fields.

Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" Food

Healthier: Health Coaching for People With Rheumatoid Arthritis to Improve Mental Well-Being

Care Improving Cognition for ADolescents on the Autism Spectrum

Determination of the Oral Irritation Potential of Two Alcohol-Free Rinses

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)

Comparison of the Effects of Oral Hygiene Regimens on Clinical, Immunomodulatory, and Microbial Outcomes and Oral Tolerance in People With Gingivitis

Tele-Collaborative Outreach to Rural Patients With Chronic Pain

Pragmatic Trial of WHT vs. PC-GE to Promote Non-Pharmacological Strategies to Treat Chronic Pain in Veterans

Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy

WearME-Pro Phase II: Remote Use Usability and Longitudinal Validation Study (Patch Form Factor).

A Multi-Modal Combination Intervention to Promote Cognitive Function in Older Intensive Care Unit Survivors

Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

Combined Effects of Diabetes Self-Management Education and Nutritional Supplementation on Visual Function and Retinopathy

Pre-exposure Prophylaxis (PrEP) at Home

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease

Botulism Toxin Injection as a Treatment for Arthritis of the Basal Thumb Joint

Neurosteroids as Novel Therapeutic Agents for Chronic Pain in OEF/OIF Veterans

Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System

Investigation and Modulation of the Mu-Opioid Mechanisms in Migraine (in Vivo)

Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB)

WEAVE NM: Heart Health and Nutrition for Life

Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence

Arizona CEAL: Linking Social Care With Healthcare Systems to Address SDOH

To Study the Efficacy & Safety of Oral NA-921 (Bionetide) in Girls and Women with Rett Syndrome